

Emergent BioSolutions Inc.
Form 4
January 06, 2016

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Bailey Sue

(Last) (First) (Middle)

400 PROFESSIONAL DR, SUITE 400

(Street)

GAITHERSBURG, MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction (Month/Day/Year)

01/04/2016

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount or Price (A) or (D)		
Common Stock <u>(1)</u>	01/04/2016		M		5,760 A \$ 11.67	34,260	D
Common Stock <u>(1) (4)</u>	01/04/2016		S		5,760 D \$ 38.97 <u>(5)</u>	28,500	D
Common Stock <u>(2)</u>	01/04/2016		M		2,880 A \$ 16.13	31,380	D
Common Stock <u>(2) (4)</u>	01/04/2016		S		2,880 D \$ 38.77 <u>(6)</u>	28,500	D
	01/04/2016		M		2,880 A	31,380	D

Edgar Filing: Emergent BioSolutions Inc. - Form 4

Common Stock ⁽³⁾					\$				
					22.02				
Common Stock ⁽³⁾ ⁽⁴⁾	01/04/2016		S	2,880	D	\$	38.46	28,500	D
						<u>(7)</u>			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Amount or Number of Shares
Stock Option ⁽¹⁾	\$ 11.67	01/04/2016		M	5,760	<u>(8)</u> 05/20/2019	Common Stock	5,760
Stock Option ⁽²⁾	\$ 16.13	01/04/2016		M	2,880	<u>(9)</u> 05/19/2020	Common Stock	2,880
Stock Option ⁽³⁾	\$ 22.02	01/04/2016		M	2,880	<u>(10)</u> 05/18/2021	Common Stock	2,880

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Bailey Sue 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG, MD 20879			X	

Signatures

/s/ Eric Burt,
attorney-in-fact

01/06/2016

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Consists of an option granted under the company's stock incentive plan on May 21, 2009.
- (2) Consists of an option granted under the company's stock incentive plan on May 20, 2010.
- (3) Consists of an option granted under the company's stock incentive plan on May 19, 2011.
- (4) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Dr. Bailey.
- (5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.58 to \$39.16, inclusive.
- (6) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.31 to \$39.11, inclusive.
- (7) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.27 to \$38.68, inclusive.
- (8) The option vested in three equal installments in May 2010, 2011 and 2012.
- (9) The option vested in three equal installments in May 2011, 2012 and 2013.
- (10) The option vested in three equal installments in May 2012, 2013 and 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.